Company Overview of Basilea Pharmaceutica International Ltd.
Basilea Pharmaceutica International Ltd. licenses, develops, distributes, markets, researches, and promotes drugs for the treatment of bacterial infections, fungal infections, and skin diseases. The company is based in Basel, Switzerland. Basilea Pharmaceutica International Ltd. operates as a subsidiary of Basilea Pharmaceutica AG.
Key Executives for Basilea Pharmaceutica International Ltd.
Head of Public Relations & Corporate Communications
Compensation as of Fiscal Year 2017.
Basilea Pharmaceutica International Ltd. Key Developments
Basilea Pharmaceutica International Ltd Extends Existing License Agreement with Pfizer for Antifungal Cresemba (Isavuconazole) to China and Asia Pacific
Dec 1 17
Basilea Pharmaceutica International Ltd. has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer Inc. for Basilea's Cresemba to include China (with Hong Kong and Macao) and sixteen countries in the Asia Pacific region. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections. Under the terms of the amendment, Basilea will receive an upfront payment of USD 3 million and is eligible to receive up to approximately USD 223 million additional payments upon achievement of pre-specified regulatory and commercial milestones related to China and the Asia Pacific region. In addition, Basilea will receive royalties in the mid-teen range on Pfizer's sales in the territory. Pfizer is granted an exclusive license to develop, manufacture and commercialize isavuconazole in China, Hong Kong and Macao, and sixteen countries in the Asia Pacific region, including Australia, India, South Korea, Singapore and Taiwan. The agreement is subject to customary regulatory approval. In June 2017, Basilea signed a license agreement with Pfizer for Europe (excluding the Nordics), Russia, Turkey and Israel. Basilea received a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and mid-teen royalties on sales.
Basilea Pharmaceutica International Ltd Announces License Agreement for Antibiotic Zevtera (Ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd
Sep 28 17
Basilea Pharmaceutica Ltd. announced that Basilea Pharmaceutica International Ltd. has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. for Basilea's antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory). Under the terms of the agreement, CR Gosun is granted an exclusive license to develop, manufacture and to commercialize ceftobiprole in the Territory. Basilea will receive an execution payment of CHF 3 million and is eligible to receive up to approximately CHF 145 million additional payments upon achievement of pre-specified regulatory and commercial milestones. CR Gosun will bear all costs for regulatory and development activities, including the conduct of clinical studies necessary for obtaining marketing authorization in the Territory. Basilea will initially supply CR Gosun at a transfer price and will be eligible for tiered double-digit royalties on product sales once CR Gosun manufactures ceftobiprole itself.
Basilea Pharmaceutica International Ltd. Enters into Distribution Agreement with Cardiome Pharma Corp. to Commercialize Antibiotic Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Sep 12 17
Basilea Pharmaceutica Ltd. announced that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea's antibiotic Zevtera(R)/Mabelio(R) (ceftobiprole) in Europe (excluding Nordic countries) and Israel. Under the terms of the agreement, Cardiome is granted an exclusive license to commercialize ceftobiprole in more than 30 countries in Europe and in Israel. Basilea will receive an upfront payment of CHF 5 million and is eligible for additional payments upon achievement of pre-specified regulatory and commercial milestones. Ceftobiprole is currently approved in 13 European countries and commercialized in Italy, France, Germany, the U.K., Austria and Switzerland under the brand name Zevtera or Mabelio. Cardiome will assume responsibility for regulatory activities and commercialization in the territory. Basilea will supply Cardiome with the product at a transfer price. Basilea remains responsible for the commercialization of ceftobiprole in the territory during the transition of the commercial activities to Cardiome, which is expected to be completed by the end of this year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|